报告无虹膜相关性青光眼患者青光眼引流装置（GDD）植入术的结果，并复习文献。
我们回顾性分析了2001年4月至2015年2月间因先天性无虹膜继发青光眼而接受GDD植入术的6例患者。手术年龄数据，性别,偏侧性,GDD植入前的手术，GDD模型，伴随的眼部疾病，视敏度,GDD植入前和术后1个月和12个月的眼内压（IOP）值，药物,随访期,在上次访问中的发现，并发症,并收集病程。
手术时的平均年龄为16.00±12.31岁（范围5-37岁）。在GDD植入前，平均IOP为33.00±12.11（范围22-50）mmHg，平均3.5±1.2药物。植入后1个月的平均IOP为16.33±4.22（范围12-24）mmHg，平均1.5±0.8药物；12个月时，使用3.0±0.8药物治疗时,平均IOP为19.50±4.76(范围15-26)mmHg.在最后一次后续访问中，IOP为21.16±4.07（范围16-26）mmHg，平均为3.33±0.51药物。平均随访时间为19.16±8.8（范围12-36）个月。手术成功率为83.3%,66.6%,1个月时50.0%，12个月,最后一次访问，分别。
GDD植入术可有效控制无虹膜性青光眼，1个月随访成功率为83.3%，1年随访成功率为66.6%。因此,应将其视为无虹膜性青光眼的初始手术治疗;临床医生应警惕伴随的眼部疾病.
To report the results obtained from glaucoma drainage device (GDD) implantation in patients with aniridia-related glaucoma and to
review the literature.
We retrospectively reviewed 6 patients who underwent GDD implantation for glaucoma secondary to congenital aniridia between April 2001 and February 2015. Data on age at surgery, gender, laterality, surgeries before GDD implantation, GDD model, concomitant ocular disorders, visual acuity, and intraocular pressure (IOP) values before and at 1 and 12 months after GDD implantation, medications, follow-up period, findings during last visit, complications, and course of disease were collected.
Mean age at surgery was 16.00±12.31 years (range 5-37 years). Mean IOP was 33.00±12.11 (range 22-50) mmHg just before the GDD implantation with a mean of 3.5±1.2 medications. Mean IOP 1 month after implantation was 16.33±4.22 (range 12-24) mmHg with a mean of 1.5±0.8 medications; at 12 months, mean IOP was 19.50±4.76 (range 15-26) mmHg with 3.0±0.8 medications. At the last follow-up visit, IOP was 21.16±4.07 (range 16-26) mmHg with a mean of 3.33±0.51 medications. Mean follow-up was 19.16±8.8 (range 12-36) months. Surgical success rates were 83.3%, 66.6%, and 50.0% at 1 month, 12 months, and the last visit, respectively.
GDD implantation was effective in controlling aniridic glaucoma with a success rate of 83.3% at 1-month follow-up and 66.6% at 1-year follow-up. Therefore, it should be considered as an initial surgical treatment for aniridic glaucoma; the clinician should be alert for concomitant ocular disorders.
PDF(Pubmed)